CSPC Group (01093): Paliperidone palmitate injection approved for listing

Zhitong Finance App News, Shiyao Group (01093) announced that the second-generation antipsychotic injection developed independently by the Group - paliperidone palmitate injection (specifications include: (1) 0.75ml: 75mg; (2) 1.0ml: 100mg; (3) 1.5ml: 150mg (based on C23H27FN4O3)) (this product) has been approved for marketing by the China National Drug Administration and is suitable for the treatment of acute and maintenance stages of schizophrenia.

Compared with traditional anti-schizophrenia drugs, this product only needs to be administered once a month, and works quickly after administration, and can be used to treat acute patients; at the same time, monthly administration significantly improves patients' medication compliance, prevents patients from skipping medication, and effectively reduces the recurrence rate and re-hospitalization rate of the disease.

This product has been listed as a recommended medication by authoritative diagnosis and treatment guidelines at home and abroad, such as the “Chinese Schizophrenia Prevention and Treatment Guidelines (2025 Edition)”. It is the preferred treatment for schizophrenia patients with poor compliance and high risk of recurrence, and has high clinical and pharmacoeconomic value.

The approval of this product will further enrich the Group's product line in the neuropsychiatric field. The Group will continue to work to develop more drugs with high clinical value to provide patients with better treatment options.